Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alamar Biosciences, Inc.ALMR · Entity 1791 | Chief Financial Officer | April 16, 2026 | April 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alamar Biosciences, Inc.
Report date April 16, 2026 · Filed April 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 37,220 |
Reported balance
After 2026-04-20 transaction · row 1
1 source rowRow 1 · 2026-04-20 · Grant · Acquired 37,220 · Balance 37,220 F1: Represents the grant of restricted stock units ("RSUs"). The RSUs vest monthly from the date of grant, subject to the reporting person's continuous service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2036-04-15 | Direct | 163,358 |
Reported balance
After 2026-04-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-16 · Grant · Acquired 163,358 · Balance 163,358 F2: Twenty-five percent of the shares subject to the option vest on April 16, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service as of each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.62 · Expires 2035-10-14 | Direct | 0 |
Reported balance
After 2026-04-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-20 · Other · Disposed 570,719 · Balance 0 F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F4: Twenty-five percent of the shares subject to the option vest on October 13, 2026, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service through each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.62 · Expires 2035-10-14 | Direct | 570,719 |
Reported balance
After 2026-04-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-04-20 · Other · Acquired 570,719 · Balance 570,719 F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock. F4: Twenty-five percent of the shares subject to the option vest on October 13, 2026, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units ("RSUs"). The RSUs vest monthly from the date of grant, subject to the reporting person's continuous service as of each such vesting date.
F2: Twenty-five percent of the shares subject to the option vest on April 16, 2027, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service as of each such vesting date.
F3: Each share of Class B Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the initial public offering of the Issuer's Common Stock.
F4: Twenty-five percent of the shares subject to the option vest on October 13, 2026, and 1/48th of the shares vest monthly thereafter, subject to the reporting person's continuous service through each such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
10x Genomics, Inc.
Report date August 22, 2024 · Filed August 26, 2024
Section 16 reporting ended · disclosed 2024-08-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 143,242 |
Reported balance
After 2024-08-22 transaction · row 1
1 source rowRow 1 · 2024-08-22 · Sale · Disposed 2,961 · Balance 143,242 F1: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2020 Filed May 5, 2020 20:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-20-027173 · doc4.xml · derivative · entry 5 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 570,000 Underlying: Class A Common Stock · 10,000 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · derivative.exercise_date: This option, originally for 600,000 shares, of which 30,000 shares have been exercised, vested as to one-fourth of the shares on October 8, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,600 | $78.70 | $204,631.44 |
DisclosureSEC source: 0001209191-20-027173 · doc4.xml · nonDerivative · entry 4 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $78.28 to $79.12. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,010 | $77.66 | $156,097.20 |
DisclosureSEC source: 0001209191-20-027173 · doc4.xml · nonDerivative · entry 3 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,600 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $77.24 to $78.13. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,390 | $76.64 | $413,109.54 |
DisclosureSEC source: 0001209191-20-027173 · doc4.xml · nonDerivative · entry 2 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,610 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $76.16 to $77.11. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| May 01, 2020 Filed May 5, 2020 20:53 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 10,000 | $5.04 | $50,400.00 |
DisclosureSEC source: 0001209191-20-027173 · doc4.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| April 21, 2020 Filed Apr 23, 2020 20:47 UTC | 10x Genomics, Inc. TXG · Entity 2172 | GrantStock Option (right to buy) · Derivative | 90,667 | $0.00 Strike: $74.58 | $0.00 |
DisclosureSEC source: 0001209191-20-025442 · doc4.xml · derivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,667 Underlying: Class A Common Stock · 90,667 shares Expires 2030-04-21 F1 · derivative.exercise_date: This option, granted pursuant to the Issuer's 2019 Omnibus Incentive Plan, vests as to one forty-eighth of the shares on May 1, 2020 and each month thereafter, subject to the reporting person continuing as a service provider through each such date. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 21:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-20-023286 · doc4.xml · derivative · entry 5 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,000 Underlying: Class A Common Stock · 10,000 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · derivative.exercise_date: This option, originally for 600,000 shares, of which 20,000 shares have been exercised, vested as to one-fourth of the shares on October 8, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 21:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 200 | $59.82 | $11,964.00 |
DisclosureSEC source: 0001209191-20-023286 · doc4.xml · nonDerivative · entry 4 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $59.80 to $59.84. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 21:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 5,110 | $58.32 | $298,024.91 |
DisclosureSEC source: 0001209191-20-023286 · doc4.xml · nonDerivative · entry 3 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $58.01 to $58.85. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 21:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 4,690 | $57.76 | $270,888.77 |
DisclosureSEC source: 0001209191-20-023286 · doc4.xml · nonDerivative · entry 2 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,310 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $57.01 to $58.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 21:13 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 10,000 | $5.04 | $50,400.00 |
DisclosureSEC source: 0001209191-20-023286 · doc4.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 01:44 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001209191-20-017552 · doc4.xml · derivative · entry 9 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 590,000 Underlying: Class A Common Stock · 10,000 shares Expires 2028-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F9 · derivative.exercise_date: This option, originally for 600,000 shares, of which 10,000 shares have been exercised, vested as to one-fourth of the shares on October 8, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 01:44 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,225 | $69.68 | $85,359.35 |
DisclosureSEC source: 0001209191-20-017552 · doc4.xml · nonDerivative · entry 8 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F8 · price: This transaction was executed in multiple trades at prices ranging from $69.42 to $70.38. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 01:44 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 900 | $68.26 | $61,432.02 |
DisclosureSEC source: 0001209191-20-017552 · doc4.xml · nonDerivative · entry 7 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,225 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F7 · price: This transaction was executed in multiple trades at prices ranging from $67.69 to $68.52. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 01:44 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 600 | $66.75 | $40,047.00 |
DisclosureSEC source: 0001209191-20-017552 · doc4.xml · nonDerivative · entry 6 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,125 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F6 · price: This transaction was executed in multiple trades at prices ranging from $66.39 to $67.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 01:44 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 700 | $65.72 | $46,001.97 |
DisclosureSEC source: 0001209191-20-017552 · doc4.xml · nonDerivative · entry 5 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,725 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $65.25 to $65.95. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 01:44 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,940 | $64.58 | $125,280.16 |
DisclosureSEC source: 0001209191-20-017552 · doc4.xml · nonDerivative · entry 4 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,425 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $64.105 to $65.00. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 01:44 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 2,835 | $63.65 | $180,438.68 |
DisclosureSEC source: 0001209191-20-017552 · doc4.xml · nonDerivative · entry 3 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,365 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F3 · price: This transaction was executed in multiple trades at prices ranging from $63.10 to $64.08. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 01:44 UTC | 10x Genomics, Inc. TXG · Entity 2172 | SaleClass A Common Stock | 1,800 | $62.77 | $112,993.02 |
DisclosureSEC source: 0001209191-20-017552 · doc4.xml · nonDerivative · entry 2 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,200 F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $62.07 to $63.06. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. Read SEC document |
| March 06, 2020 Filed Mar 10, 2020 01:44 UTC | 10x Genomics, Inc. TXG · Entity 2172 | Exercise / conversionClass A Common Stock | 10,000 | $5.04 | $50,400.00 |
DisclosureSEC source: 0001209191-20-017552 · doc4.xml · nonDerivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 20:16 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $11.48 | $0.00 |
DisclosureSEC source: 0000899243-19-023633 · doc4.xml · derivative · entry 4 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Class A Common Stock · 20,000 shares Expires 2029-05-10 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. F3 · derivative.exercise_date: One forty-eighth of the shares subject to the option vested on May 1, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 20:16 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $11.48 | $0.00 |
DisclosureSEC source: 0000899243-19-023633 · doc4.xml · derivative · entry 3 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 20,000 shares Expires 2029-05-10 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. F3 · derivative.exercise_date: One forty-eighth of the shares subject to the option vested on May 1, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 20:16 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherStock Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0000899243-19-023633 · doc4.xml · derivative · entry 2 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,000 Underlying: Class A Common Stock · 600,000 shares Expires 2028-11-02 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. F2 · derivative.exercise_date: One-fourth of the shares subject to the option vest on October 8, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. This option may be exercised prior to vesting, subject to the Issuer's right to repurchase unvested shares. F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. Read SEC document |
| September 16, 2019 Filed Sep 16, 2019 20:16 UTC | 10x Genomics, Inc. TXG · Entity 2172 | OtherStock Option (right to buy) · Derivative | 600,000 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0000899243-19-023633 · doc4.xml · derivative · entry 1 McAnear Justin J. · CIK 0001786386 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 600,000 shares Expires 2028-11-02 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. F2 · derivative.exercise_date: One-fourth of the shares subject to the option vest on October 8, 2019 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date. This option may be exercised prior to vesting, subject to the Issuer's right to repurchase unvested shares. F1 · derivative.underlying: Pursuant to a reclassification exempt under Rule 16b-7, each share of Class B Common Stock was reclassified into one share of Class A Common Stock immediately prior to the completion of the Issuer's initial public offering. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.